Srividyameena Haridoss, Mladen I. Yovchev, Hannah Schweizer, Sabreen Megherhi, Maria Beecher, Joseph Locker, Michael Oertel – 3 November 2017 – Activin A, a multifunctional cytokine, plays an important role in hepatocyte growth suppression and is involved in liver size control. The present study was aimed to determine the cell location of activin A in the normal rat liver microenvironment and the contribution of activin A signaling to the hepatocyte phenotype to obtain insight into molecular mechanisms.

3 November 2017

Hilda E. Ghadieh, Harrison T. Muturi, Lucia Russo, Christopher C. Marino, Simona S. Ghanem, Saja S. Khuder, Julie C. Hanna, Sukanta Jash, Vishwajeet Puri, Garrett Heinrich, Cara Gatto‐Weis, Kevin Y. Lee, Sonia M. Najjar – 2 November 2017 – Exenatide, a glucagon‐like peptide‐1 receptor agonist, induces insulin secretion. Its role in insulin clearance has not been adequately examined. Carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) promotes hepatic insulin clearance to maintain insulin sensitivity.

Kirk J. Wangensteen, Yue J. Wang, Zhixun Dou, Amber W. Wang, Elham Mosleh‐Shirazi, Max A. Horlbeck, Luke A. Gilbert, Jonathan S. Weissman, Shelley L. Berger, Klaus H. Kaestner – 1 November 2017 – Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated 9 activation (CRISPRa) systems have enabled genetic screens in cultured cell lines to discover and characterize drivers and inhibitors of cancer cell growth.

Elliot B. Tapper, Neehar D. Parikh, Neil Sengupta, Jessica Mellinger, David Ratz, Anna S.‐F. Lok, Grace L. Su – 1 November 2017 – Over 40% of patients with cirrhosis will develop hepatic encephalopathy (HE). HE is associated with decreased survival, falls, motor vehicle accidents, and frequent hospitalization. Accordingly, we aimed to develop a tool to risk‐stratify patients for HE development.

Reben Raeman, Frank A. Anania – 1 November 2017

Jorge Matias Caviglia, Jun Yan, Myoung‐Kuk Jang, Geum‐Youn Gwak, Silvia Affo, Lexing Yu, Peter Olinga, Richard A. Friedman, Xin Chen, Robert F. Schwabe – 1 November 2017 – Fibrosis and cancer represent two major complications of chronic liver disease. MicroRNAs have been implicated in the development of fibrosis and cancer, thus constituting potential therapeutic targets.

Marco Carbone, Giulia Bonato, Pietro Invernizzi – 1 November 2017

Yao Lu, Zhou Jiang, Haijiang Dai, Rujia Miao, Jingxian Shu, Haotian Gu, Xing Liu, Zhijun Huang, Guoping Yang, Alex F. Chen, Hong Yuan, Ying Li, Jingjing Cai – 1 November 2017 – Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent liver pathology characterized by hepatic steatosis and commonly accompanied by systematic inflammation and metabolic disorder. Despite an accumulating number of studies, no pharmacological strategy is available to treat this condition in the clinic.

Jillian L. Ellis, Kevin E. Bove, Erin G. Schuetz, Daniel Leino, C. Alexander Valencia, John D. Schuetz, Alexander Miethke, Chunyue Yin – 1 November 2017 – Bile salt export pump (BSEP) adenosine triphosphate–binding cassette B11 (ABCB11) is a liver‐specific ABC transporter that mediates canalicular bile salt excretion from hepatocytes. Human mutations in ABCB11 cause progressive familial intrahepatic cholestasis type 2.